Literature DB >> 26160868

Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations.

Nicole Sonneveld1, Sanja Stanojevic2, Reshma Amin3, Paul Aurora4, Jane Davies5, J Stuart Elborn6, Alex Horsley7, Philipp Latzin8, Katherine O'Neill6, Paul Robinson9, Emma Scrase4, Hiran Selvadurai9, Padmaja Subbarao10, Liam Welsh11, Sophie Yammine8, Felix Ratjen12.   

Abstract

Pulmonary exacerbations are important clinical events for cystic fibrosis (CF) patients. Studies assessing the ability of the lung clearance index (LCI) to detect treatment response for pulmonary exacerbations have yielded heterogeneous results. Here, we conduct a retrospective analysis of pooled LCI data to assess treatment with intravenous antibiotics for pulmonary exacerbations and to understand factors explaining the heterogeneous response.A systematic literature search was performed to identify prospective observational studies. Factors predicting the relative change in LCI and spirometry were evaluated while adjusting for within-study clustering.Six previously reported studies and one unpublished study, which included 176 pulmonary exacerbations in both paediatric and adult patients, were included. Overall, LCI significantly decreased by 0.40 units (95% CI -0.60- -0.19, p=0.004) or 2.5% following treatment. The relative change in LCI was significantly correlated with the relative change in forced expiratory volume in 1 s (FEV1), but results were discordant in 42.5% of subjects (80 out of 188). Higher (worse) baseline LCI was associated with a greater improvement in LCI (slope: -0.9%, 95% CI -1.0- -0.4%).LCI response to therapy for pulmonary exacerbations is heterogeneous in CF patients; the overall effect size is small and results are often discordant with FEV1.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26160868     DOI: 10.1183/09031936.00211914

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

Review 1.  Building global development strategies for cf therapeutics during a transitional cftr modulator era.

Authors:  N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart
Journal:  J Cyst Fibros       Date:  2020-06-07       Impact factor: 5.482

2.  Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).

Authors:  Laura S Gold; Donald L Patrick; Ryan N Hansen; Christopher H Goss; Larry Kessler
Journal:  J Cyst Fibros       Date:  2019-05-22       Impact factor: 5.482

3.  Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations.

Authors:  Hartmut Grasemann; Pierluigi Ciet; Reshma Amin; Nancy McDonald; Michelle Klingel; Harm A W M Tiddens; Felix Ratjen; Lars Grosse-Wortmann
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

4.  Evaluation of surrogate measures of pulmonary function derived from electrical impedance tomography data in children with cystic fibrosis.

Authors:  Peter A Muller; Jennifer L Mueller; Michelle Mellenthin; Rashmi Murthy; Michael Capps; Brandie D Wagner; Melody Alsaker; Robin Deterding; Scott D Sagel; Jordana Hoppe
Journal:  Physiol Meas       Date:  2018-04-26       Impact factor: 2.833

5.  Progression of Lung Disease in Preschool Patients with Cystic Fibrosis.

Authors:  Sanja Stanojevic; Stephanie D Davis; George Retsch-Bogart; Hailey Webster; Miriam Davis; Robin C Johnson; Renee Jensen; Maria Ester Pizarro; Mica Kane; Charles C Clem; Leah Schornick; Padmaja Subbarao; Felix A Ratjen
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

6.  Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study.

Authors:  Katherine O'Neill; Fidelma Moran; Michael M Tunney; J Stuart Elborn; Ian Bradbury; Damian G Downey; Jackie Rendall; Judy M Bradley
Journal:  BMJ Open Respir Res       Date:  2017-01-12

7.  Key paediatric messages from Amsterdam.

Authors:  Jonathan Grigg; Jürg Barben; Kajsa Bohlin; Mark L Everard; Graham Hall; Mariëlle Pijnenburg; Kostas N Priftis; Franca Rusconi; Fabio Midulla
Journal:  ERJ Open Res       Date:  2016-04-29

8.  Maximal mid-expiratory flow is a surrogate marker of lung clearance index for assessment of adults with bronchiectasis.

Authors:  Wei-Jie Guan; Jing-Jing Yuan; Yong-Hua Gao; Hui-Min Li; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  Sci Rep       Date:  2016-06-24       Impact factor: 4.379

9.  Ciprofloxacin dry powder inhaler in cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  BMJ Open Respir Res       Date:  2016-01-04

10.  Effect of enterovirus D68 on Lung Clearance Index in patients with cystic fibrosis: A case report.

Authors:  Danielle M Goetz; Shipra Singh; Daniel Sheehan
Journal:  Respir Med Case Rep       Date:  2015-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.